AbCelex Technologies Inc. (www.abcelex.com) is a privately-owned Canadian biotechnology company that has developed a proprietary camelid antibody platform and has engineered and tested an orally available class of antibodies in two infectious disease programs with proof of concept studies completed. AbCelex has demonstrated successful expression of more than 50 diverse protein target antigens, generated more than 10 large functional libraries of immune and naïve origin. Our platform enables to rationally design and optimise discovery and therapeutic candidates with extended half-live, increased proteolytic stability, and tailored target binding affinity. Additionally, the ability to interchange antibody subunits, AbCelex can rapidly and efficiently create multi-specific and multivalent therapeutic agents suitable for a range of therapeutic applications. Company currently has one immuno-recruiting platform in early preclinical development.